Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Heather Jacene
Radiopharmaceutical Therapy: Rapid Growth, Rising Challenges, and the Critical Need for Expertise
The field of theranostics dates back over 80 y, when Hertz and Roberts first used radioactive iodine to treat thyroid disease. Recent theranostic approvals for neuroendocrine tumors and prostate cancer have expanded the use of radiopharmaceutical therapy (RPT), and there is significant near-term potential for further expansion across multiple tumor types.
Summary: SNMMI/ACNM Procedure Standard for Posttreatment Imaging of 177Lu-Based Radiopharmaceuticals
RECOMMENDATIONS Based on the comprehensive review of current practices, our expert panel recommends the following clinical actions to support the effective implementation of posttreatment imaging in 177Lu-based radiopharmaceutical therapies. Table 3 provides a summary of these key recommendations. 1.
Radiopharmaceutical Therapies: Safety, Education, and Collaboration in Oncology - Heather Jacene & Neha Vapiwala
Read the Full Video Transcript Phillip J. Koo: Hi. I'm Phillip Koo, and welcome to UroToday. We have a really special discussion that we're recording today focusing on radiopharmaceuticals in oncology, and specifically prostate cancer. With the introduction and growth of RLT in prostate cancer, there are two major specialties that are obviously authorized to provide these services, and that includes nuclear medicine and radiation oncology.
The Current and Future Roles of Precision Oncology in Advanced Breast Cancer
MOLECULAR IMAGING AS A BIOMARKER: KEY TERMINOLOGY Precision medicine uses biomarkers, defined as a “characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or biological responses to an exposure or intervention, including therapeutic interventions” (14). The FDA–National Institutes of Health Biomarker Working Group established the BEST (Biomarkers, EndpointS, and other Tools) Resource to provide a comprehensive glossary of all biomarker types (14).
Imaging Androgen Receptors in Breast Cancer with 18F-Fluoro-5α-Dihydrotestosterone PET: A Pilot Study
Abstract Most breast cancers express androgen receptors (ARs). This prospective imaging substudy explored imaging of ARs with 18F-fluoro-5α-dihydrotestosterone (18F-FDHT) PET in patients with metastatic breast cancer (MBC) receiving selective AR modulation (SARM) therapy (GTx-024). Methods: Eleven postmenopausal women with estrogen receptor–positive MBC underwent 18F-FDHT PET/CT at baseline and at 6 and 12 wk after starting SARM therapy. Abnormal tumor 18F-FDHT uptake was quantified using SUVmax.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Heather
Contact Heather, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack